Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 149 Neoplasm Metastasis 22 Neoplasms 17 Sarcoma 10 Ovarian Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Endometrial Neoplasms 6 Colorectal Neoplasms 6 Prostatic Neoplasms 5 Melanoma 5 Lymphoma, Non-Hodgkin 5 Head and Neck Neoplasms 5 Breast Diseases 5 Sarcoma, Ewing 4 Recurrence 4 Multiple Myeloma 4 Medulloblastoma 4 Lung Neoplasms 4 Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 3 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Osteosarcoma 3 Neuroblastoma 3 Liposarcoma 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3

Interventions

Cyclophosphamide 21 blinatumomab 16 Cytarabine 14 fludarabine 13 Azacitidine 11 venetoclax 9 fludarabine phosphate 9 Blood Specimen Collection 8 Rituximab 7 Methotrexate 7 Dexamethasone 7 Daunorubicin 7 Lenalidomide 6 Vincristine 5 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Liquid Biopsy 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Doxorubicin 3 Cladribine 3 Chemotherapy, Adjuvant 3 Busulfan 3 Asparaginase 3 trastuzumab deruxtecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841148 2025-03-11

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡